Kallelse till årsstämma i Biovica International AB

Styrelsen i Biovica International AB, org.nr 556774-6150, kallar härmed till årsstämma den 27 augusti 2020 kl. 16:00 i bolagets lokaler på Dag Hammarskjölds väg 54B, Uppsala Science Park, Uppsala.

2020-07-22T06:00:00+02:00July 22nd, 2020 06:00|

Notice to AGM for Biovica International AB

The Board of Directors of Biovica International AB, corporate identity number 556774-6150, hereby convenes the Annual General Meeting on 27 August 2020 at 16:00 in the company's premises at Dag Hammarskjölds väg 54B, Uppsala Science Park, Uppsala.

2020-07-22T06:00:00+02:00July 22nd, 2020 06:00|

Biovica International AB – Annual Report for the fiscal year 2019/2020 published

Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com/investor-relations/financials/ ContactAnders Rylander, CEOPhone: +46-18-444 48 35E-mail: anders.rylander@biovica.comCecilia Driving, EVP CFO/HR/IRPhone +46-73-125 92 47E-mail: cecilia.driving@biovica.com Biovica – Treatment decisions with greater confidenceBiovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a [...]

2020-06-30T06:00:00+02:00June 30th, 2020 06:00|

Biovica International AB – Årsredovisning för verksamhetsåret 2019/2020 publicerad

Årsredovisning för verksamhetsåret 2019/2020 för Biovica International AB publiceras idag på vår webbplats https://biovica.com/investor-relations/financials/ KontaktAnders Rylander, VDTelefon: 018-444 48 35E-post: anders.rylander@biovica.comCecilia Driving, EVP CFO/HR/IRTelefon 073-125 92 47E-post: cecilia.driving@biovica.com Biovica – Behandlingsbeslut med större säkerhetBiovica utvecklar och kommersialiserar blodbaserade test i syfte att utvärdera effekten av cancerbehandlingar. Genom att mäta en biomarkör som finns i blodet ger [...]

2020-06-30T06:00:00+02:00June 30th, 2020 06:00|

Biovica completes analytical validation as part of FDA application

Biovica, active in cancer diagnostics, today announced that the analytical validation of the blood test DiviTum has been completed. The validation aims to verify technical and precision requirements defined in consultation with the US Food and Drug Administration (FDA). The analytical validation is an important part of the application for US market approval.

2020-06-17T06:00:00+02:00June 17th, 2020 06:00|

Biovica har slutfört analytisk validering inför FDA-ansökan

Biovica, verksamt inom cancerdiagnostik, meddelade idag att den analytiska valideringen av blodtestet DiviTum® har slutförts. Valideringen har utförts för att verifiera tekniska krav och precisionskrav som definierats i samråd med det amerikanska läkemedelsverket, FDA. Den analytiska valideringen är en viktig del av ansökan om ett amerikanskt marknadsgodkännande.

2020-06-17T06:00:00+02:00June 17th, 2020 06:00|

Biovica International AB: Redeye Initiates Coverage of Biovica

Redeye initiates coverage of cancer diagnostics firm Biovica with base case of SEK 24. The shares have spiked some 140 percent YTD on the back of increasing investor optimism ahead of a possible US launch next year. While we see room for a slight pull-back short-term, a potential marketing approval in the US for blood-based cancer diagnostic test DiviTum within the next 6-12 months is a major catalyst for significant further upside to our valuation. Ongoing clinical validation to complete the submission to the FDA could provide important clues already in the next few months.

2020-05-25T05:57:16+02:00May 25th, 2020 05:57|